Advantage Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | $14K | Hold |
150
| – | – | 0.01% | 597 |
|
|
2019
Q2 | $13K | Hold |
150
| – | – | 0.01% | 622 |
|
|
2019
Q1 | $13K | Hold |
150
| – | – | 0.01% | 613 |
|
|
2018
Q4 | $11K | Hold |
150
| – | – | 0.01% | 636 |
|
|
2018
Q3 | $18K | Hold |
150
| – | – | 0.01% | 597 |
|
|
2018
Q2 | $15K | Hold |
150
| – | – | 0.01% | 595 |
|
|
2018
Q1 | $12K | Hold |
150
| – | – | ﹤0.01% | 647 |
|
|
2017
Q4 | $12K | Sell |
150
-20
| -12% | -$1.6K | ﹤0.01% | 658 |
|
|
2017
Q3 | $10K | Hold |
170
| – | – | ﹤0.01% | 689 |
|
|
2017
Q2 | $8K | Buy |
170
+20
| +13% | +$941 | ﹤0.01% | 750 |
|
|
2017
Q1 | $7K | Hold |
150
| – | – | ﹤0.01% | 754 |
|
|
2016
Q4 | $6K | Hold |
150
| – | – | ﹤0.01% | 722 |
|
|
2016
Q3 | $8K | Sell |
150
-40
| -21% | -$2.13K | ﹤0.01% | 658 |
|
|
2016
Q2 | $9K | Buy |
190
+40
| +27% | +$1.9K | ﹤0.01% | 610 |
|
|
2016
Q1 | $6K | Hold |
150
| – | – | ﹤0.01% | 659 |
|
|
2015
Q4 | $8K | Hold |
150
| – | – | ﹤0.01% | 608 |
|
|
2015
Q3 | $6K | Buy |
+150
| New | +$6K | ﹤0.01% | 630 |
|